摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,4-二(2-氯乙氧基)-2,5-二溴苯 | 178557-12-5

中文名称
1,4-二(2-氯乙氧基)-2,5-二溴苯
中文别名
1,4-二溴-2,5-双(2-氯乙氧基)苯
英文名称
1,4-bis(2-chloroethoxy)-2,5-dibromobenzene
英文别名
1,4-dibromo-2,5-bis(2-chloroethoxy)benzene
1,4-二(2-氯乙氧基)-2,5-二溴苯化学式
CAS
178557-12-5
化学式
C10H10Br2Cl2O2
mdl
——
分子量
392.902
InChiKey
IGJLUNFUSYBNGH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    120 °C
  • 沸点:
    407.4±40.0 °C(Predicted)
  • 密度:
    1.741±0.06 g/cm3(Predicted)
  • 溶解度:
    可溶于丙酮、氯仿、二氯甲烷、乙酸乙酯

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    16
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    18.5
  • 氢给体数:
    0
  • 氢受体数:
    2

SDS

SDS:54fabef0942a9d2d9b8acf1e9b444afb
查看

反应信息

  • 作为反应物:
    参考文献:
    名称:
    新型四氢苯并二呋喃-咪唑鎓盐衍生物的合成及细胞毒活性。
    摘要:
    提出了一系列新颖的4-取代的2,3,6,7-四氢苯并[1,2-b; 4,5-b']二呋喃-1H-咪唑鎓盐的合成。在体外针对一组人类肿瘤细胞系评估了化合物的生物学特性。结果表明5,6-二甲基苯并咪唑环或2-甲基苯并咪唑环以及用2-萘甲基取代基或2-萘甲酰基取代基取代咪唑基-3-位对于细胞毒性活性是重要的。值得注意的是,3-(2-萘基甲基)-1-(((2,3,6,7-四氢苯并[1,2-b; 4,5-b']二呋喃-4-基)甲基)-1H-5,发现六甲基二甲基苯并咪唑-3-溴化铵(42)是针对五种人类肿瘤细胞系的最有效衍生物,IC50值为1.06-4.34μM,对SMMC-7721,A549和SW480细胞系更具选择性。3-(2-萘甲酰基)-1-(((2,3,6,7-四氢苯并[1,2-b; 4,5-b']二呋喃-4-基)甲基)-1H-2-甲基苯并咪唑-3-溴化铵(37)对SMMC-7721和MCF-
    DOI:
    10.1016/j.bmcl.2017.02.053
  • 作为产物:
    描述:
    对苯二酚铁粉potassium carbonate 作用下, 以 四氯化碳丙酮 为溶剂, 反应 29.0h, 生成 1,4-二(2-氯乙氧基)-2,5-二溴苯
    参考文献:
    名称:
    新型四氢苯并二呋喃-咪唑鎓盐衍生物的合成及细胞毒活性。
    摘要:
    提出了一系列新颖的4-取代的2,3,6,7-四氢苯并[1,2-b; 4,5-b']二呋喃-1H-咪唑鎓盐的合成。在体外针对一组人类肿瘤细胞系评估了化合物的生物学特性。结果表明5,6-二甲基苯并咪唑环或2-甲基苯并咪唑环以及用2-萘甲基取代基或2-萘甲酰基取代基取代咪唑基-3-位对于细胞毒性活性是重要的。值得注意的是,3-(2-萘基甲基)-1-(((2,3,6,7-四氢苯并[1,2-b; 4,5-b']二呋喃-4-基)甲基)-1H-5,发现六甲基二甲基苯并咪唑-3-溴化铵(42)是针对五种人类肿瘤细胞系的最有效衍生物,IC50值为1.06-4.34μM,对SMMC-7721,A549和SW480细胞系更具选择性。3-(2-萘甲酰基)-1-(((2,3,6,7-四氢苯并[1,2-b; 4,5-b']二呋喃-4-基)甲基)-1H-2-甲基苯并咪唑-3-溴化铵(37)对SMMC-7721和MCF-
    DOI:
    10.1016/j.bmcl.2017.02.053
点击查看最新优质反应信息

文献信息

  • LUMINESCENT COMPOUNDS
    申请人:Terpetschnig Ewald A.
    公开号:US20100266507A1
    公开(公告)日:2010-10-21
    Luminescent reporter compounds that are rotaxanes having the structure where B—Z—C is a reporter molecule based on a cyanine, squaric acid, or other reporter, and K is a macrocycle that encircles and interlocks with the reporter molecule. Applications of the reporter compounds are provided, as well as reactive intermediates used to synthesize the reporter compounds, and methods of synthesizing the reporter compounds.
    具有以下结构的轮烷的发光报告化合物,其中B—Z—C是基于青菁、方酸或其他报告物质的报告分子,K是环绕并与报告分子相互锁定的大环。提供了报告化合物的应用,以及用于合成报告化合物的反应中间体和合成报告化合物的方法。
  • Enantiospecific Synthesis and Pharmacological Evaluation of a Series of Super-Potent, Conformationally Restricted 5-HT<sub>2A/2C</sub> Receptor Agonists
    作者:James J. Chambers、Deborah M. Kurrasch-Orbaugh、Matthew A. Parker、David E. Nichols
    DOI:10.1021/jm000491y
    日期:2001.3.1
    D- or L-alanyl chloride, followed by ketone reduction and N-deprotection. The enantiomers demonstrated modest stereoselectivity at the two receptors. Several general trends within these classes of new compounds were observed during their pharmacological investigation. For most pairs of optical isomers tested, the R-enantiomers of the compounds containing heterocycle 7 bound with only slightly higher
    配体对5-HT(2A)或5-HT(2C)激动剂结合位点的亲和力通过修饰典型的致幻性苯丙胺(如4b(DOB))中的2,5-氧取代基来增强。相对于母体2,5-二甲氧基化合物,构象柔性的2,5-二甲氧基取代基限制为稠合的二氢呋喃环通常导致效力增加。这些芳基烷基胺的纯对映体是通过对映体特异性合成得到的,该合成涉及用N-三氟乙酰基保护的D-或L-丙氨酰氯对杂环核7进行酰化,然后进行酮还原和N-脱保护。对映异构体在两个受体上显示适度的立体选择性。在它们的药理研究过程中,观察到了这些新化合物类别中的一些一般趋势。对于大多数测试的光学异构体对,在5-HT(2A)和5-HT(2C)受体上,含杂环7的化合物的R-对映体仅比其S-对映体具有更高的亲和力。同样,功能研究表明,与S-对映体相比,R-对映体通常显示出更高的效价。这些芳基烷基胺的二氢呋喃环的芳香化进一步增加了亲和力和效力。仅有少数化合物是完全激动剂,其
  • SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME
    申请人:The University of Queensland
    公开号:EP3578547A1
    公开(公告)日:2019-12-11
    The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.
    本发明提供了某些磺酰脲类及相关化合物,它们在抑制 NLRP3 炎性体活化方面具有优势特性并显示出有用的活性。此类化合物可用于治疗多种疾病,在这些疾病中,炎症过程或更具体地说是 NLRP3 炎症体被认为是一个关键因素。
  • Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
    申请人:Feng Zixia
    公开号:US20060009503A1
    公开(公告)日:2006-01-12
    The present invention provides benzodifuran imidazoline derivatives and benzofuran imidazoline derivatives for lowering intraocular pressure and providing ocular neuroprotection.
    本发明提供了苯并二呋喃咪唑啉衍生物和苯并呋喃咪唑啉衍生物,用于降低眼压和提供眼神经保护。
  • Dihydrobenzofuran Analogues of Hallucinogens. 3. Models of 4-Substituted (2,5-Dimethoxyphenyl)alkylamine Derivatives with Rigidified Methoxy Groups
    作者:Aaron P. Monte、Danuta Marona-Lewicka、Matthew A. Parker、David B. Wainscott、David L. Nelson、David E. Nichols
    DOI:10.1021/jm960199j
    日期:1996.1.1
    Tetrahydrobenzodifuran functionalities were employed as conformationally restricted bioisosteres of the aromatic methoxy groups in prototypical hallucinogenic phenylalkylamines 1 and 2. Thus, a series of 8-substituted 1-(2,3,6,7-tetrahydrobenzo[ 1,2-b:4,5-b']difuran-4-yl)-2-aminoalkanes (7a-e) were prepared and evaluated for activity in the two-lever drug discrimination paradigm in rats trained to discriminate saline from LSD tartrate (0.08 mg/kg) and for the ability to displace [H-3]ketanserin from rat cortical homogenate 5-HT2A receptors and [(3)H3-8-OH-DPAT from rat hippocampal homogenate 5-HT1A receptors. In addition, 1-(8-(bromo-2,3,6,7-tetrahydrobenzo[1,2-b:4,5- (7b), which was found to be extremely potent in the rat in vivo assays, was evaluated for its ability to compete with [I-125][DOI and [H-3]ketanserin binding to cells expressing cloned human 5-HT2A, 5-H-2B, and 5-HT2C receptors. All of the dihydrofuranyl compounds having a hydrophobic substituent para to the alkylamine side chain had activities in both the in vitro and in vivo assays that equaled or surpassed the activity of the analogous conformationally flexible parent compounds. For example, 7b substituted for LSD in the drug discrimination assay with an ED(50) Of 61 nmol/kg and had K-i values in the nanomolar to subnanomolar range for the displacement of radioligand from rat and human 5-HT2 receptors, making it one of the most potent hallucinogen-like phenylalkylamine derivatives reported to date. The results suggest that the dihydrofuran rings in these pew analogues effectively model the active binding conformations of the methoxy groups of the parent compounds 1 and 2. In addition, the results provide information about the topography and relative orientation of residues involved in agonist binding in the serotonin 5-HT2 receptors.
查看更多